{"version":"1.0","type":"link","title":"Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options.","author_name":"Easaw JC 외","author_url":"https://prs-insight.online/author/Easaw%20JC","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/123404","thumbnail_width":1200,"thumbnail_height":630}